Overview

Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)

Status:
Completed

Trial end date:
2015-10-05

Target enrollment:

Participant gender:

Summary

This study is designed to determine whether ulcerative colitis participants prefer delivery of golimumab via a prefilled syringe or the Smartject™ device.

Phase:

Phase 4

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Antibodies, Monoclonal
Golimumab